Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus

Mina Yabusaki, Jun Sato, Atsushi Kohyama, Takashi Kojima, Daisuke Nobuoka, Toshiaki Yoshikawa, Yu Sawada, Katsuhiro Murakami, Keigo Gohda, Takatsugu Okegawa, Masaru Nakamura, Kiyoshi Takamatsu, Masaaki Ito, Kazuhiro Kaneko, Tetsuya Nakatsura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We developed a detection method for circulating tumor cells (CTCs) using the telomerase-specific adenovirus OBP-401. This recombinant virus has a telomerase promoter at the 5'-end of the viral genome and GFP at the 3'-end. To date, CTC enumeration using OBP-401 has shown prognostic impact for gastric and small cell lung cancer patients. In the present study, peripheral blood samples from patients with eight types of cancer, including some cancers previously untested with OBP-401 (i.e., esophagus, pancreas, and prostate cancers) were subjected to this method in order to evaluate its versatility. It was recently discovered that some white blood cells (WBCs) false-positively react with OBP-401. Although anti-CD45 antibodies can absorb these adverse cells from peripheral blood, the simplicity of the OBP-401 method would be diminished by the introduction of antibody treatment. Therefore, we evaluated another approach to minimize the false positivity of WBCs. Seven anti-CD antibodies were employed to stain the species of WBCs that false-positively reacted with OBP-401. We revealed that the false-positively reacted WBCs were monocytes in the peripheral blood of both healthy subjects and cancer patients. Based on a size distribution analysis of the GFP-positive monocytes, the size criterion for CTCs using OBP-401 was defined to be a cellular diameter >8.4 μm. In total, 43% of 86 cancer patients examined in the present study were CTC-positive using this definition. CTCs were enumerated from peripheral blood samples collected from patients with each of the eight types of cancer; the detectability of CTCs for esophagus, pancreas and prostate cancers by the OBP-401 method was confirmed for the first time in the present study. However, no clear correlation between CTC positivity and the clinical characteristics of patients with any type of cancer was observed because of the small number of patients with each type of cancer. An additional clinical study will be conducted to confirm the clinical meaning of CTCs enumerated by OBP-401.

Original languageEnglish
Pages (from-to)1772-1778
Number of pages7
JournalOncology Reports
Volume32
Issue number5
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Circulating Neoplastic Cells
Telomerase
Adenoviridae
Neoplasms
Leukocytes
Esophageal Neoplasms
Pancreatic Neoplasms
Monocytes
Anti-Idiotypic Antibodies
Prostatic Neoplasms
Viral Genome
Small Cell Lung Carcinoma
Blood Cells
Stomach
Healthy Volunteers
Coloring Agents
Viruses
Antibodies

Keywords

  • Adenovirus
  • Circulating tumor cells
  • OBP-401
  • Telomerase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. / Yabusaki, Mina; Sato, Jun; Kohyama, Atsushi; Kojima, Takashi; Nobuoka, Daisuke; Yoshikawa, Toshiaki; Sawada, Yu; Murakami, Katsuhiro; Gohda, Keigo; Okegawa, Takatsugu; Nakamura, Masaru; Takamatsu, Kiyoshi; Ito, Masaaki; Kaneko, Kazuhiro; Nakatsura, Tetsuya.

In: Oncology Reports, Vol. 32, No. 5, 01.11.2014, p. 1772-1778.

Research output: Contribution to journalArticle

Yabusaki, M, Sato, J, Kohyama, A, Kojima, T, Nobuoka, D, Yoshikawa, T, Sawada, Y, Murakami, K, Gohda, K, Okegawa, T, Nakamura, M, Takamatsu, K, Ito, M, Kaneko, K & Nakatsura, T 2014, 'Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus', Oncology Reports, vol. 32, no. 5, pp. 1772-1778. https://doi.org/10.3892/or.2014.3436
Yabusaki, Mina ; Sato, Jun ; Kohyama, Atsushi ; Kojima, Takashi ; Nobuoka, Daisuke ; Yoshikawa, Toshiaki ; Sawada, Yu ; Murakami, Katsuhiro ; Gohda, Keigo ; Okegawa, Takatsugu ; Nakamura, Masaru ; Takamatsu, Kiyoshi ; Ito, Masaaki ; Kaneko, Kazuhiro ; Nakatsura, Tetsuya. / Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. In: Oncology Reports. 2014 ; Vol. 32, No. 5. pp. 1772-1778.
@article{9116ca37606649fcae8ef1d25366033c,
title = "Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus",
abstract = "We developed a detection method for circulating tumor cells (CTCs) using the telomerase-specific adenovirus OBP-401. This recombinant virus has a telomerase promoter at the 5'-end of the viral genome and GFP at the 3'-end. To date, CTC enumeration using OBP-401 has shown prognostic impact for gastric and small cell lung cancer patients. In the present study, peripheral blood samples from patients with eight types of cancer, including some cancers previously untested with OBP-401 (i.e., esophagus, pancreas, and prostate cancers) were subjected to this method in order to evaluate its versatility. It was recently discovered that some white blood cells (WBCs) false-positively react with OBP-401. Although anti-CD45 antibodies can absorb these adverse cells from peripheral blood, the simplicity of the OBP-401 method would be diminished by the introduction of antibody treatment. Therefore, we evaluated another approach to minimize the false positivity of WBCs. Seven anti-CD antibodies were employed to stain the species of WBCs that false-positively reacted with OBP-401. We revealed that the false-positively reacted WBCs were monocytes in the peripheral blood of both healthy subjects and cancer patients. Based on a size distribution analysis of the GFP-positive monocytes, the size criterion for CTCs using OBP-401 was defined to be a cellular diameter >8.4 μm. In total, 43{\%} of 86 cancer patients examined in the present study were CTC-positive using this definition. CTCs were enumerated from peripheral blood samples collected from patients with each of the eight types of cancer; the detectability of CTCs for esophagus, pancreas and prostate cancers by the OBP-401 method was confirmed for the first time in the present study. However, no clear correlation between CTC positivity and the clinical characteristics of patients with any type of cancer was observed because of the small number of patients with each type of cancer. An additional clinical study will be conducted to confirm the clinical meaning of CTCs enumerated by OBP-401.",
keywords = "Adenovirus, Circulating tumor cells, OBP-401, Telomerase",
author = "Mina Yabusaki and Jun Sato and Atsushi Kohyama and Takashi Kojima and Daisuke Nobuoka and Toshiaki Yoshikawa and Yu Sawada and Katsuhiro Murakami and Keigo Gohda and Takatsugu Okegawa and Masaru Nakamura and Kiyoshi Takamatsu and Masaaki Ito and Kazuhiro Kaneko and Tetsuya Nakatsura",
year = "2014",
month = "11",
day = "1",
doi = "10.3892/or.2014.3436",
language = "English",
volume = "32",
pages = "1772--1778",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus

AU - Yabusaki, Mina

AU - Sato, Jun

AU - Kohyama, Atsushi

AU - Kojima, Takashi

AU - Nobuoka, Daisuke

AU - Yoshikawa, Toshiaki

AU - Sawada, Yu

AU - Murakami, Katsuhiro

AU - Gohda, Keigo

AU - Okegawa, Takatsugu

AU - Nakamura, Masaru

AU - Takamatsu, Kiyoshi

AU - Ito, Masaaki

AU - Kaneko, Kazuhiro

AU - Nakatsura, Tetsuya

PY - 2014/11/1

Y1 - 2014/11/1

N2 - We developed a detection method for circulating tumor cells (CTCs) using the telomerase-specific adenovirus OBP-401. This recombinant virus has a telomerase promoter at the 5'-end of the viral genome and GFP at the 3'-end. To date, CTC enumeration using OBP-401 has shown prognostic impact for gastric and small cell lung cancer patients. In the present study, peripheral blood samples from patients with eight types of cancer, including some cancers previously untested with OBP-401 (i.e., esophagus, pancreas, and prostate cancers) were subjected to this method in order to evaluate its versatility. It was recently discovered that some white blood cells (WBCs) false-positively react with OBP-401. Although anti-CD45 antibodies can absorb these adverse cells from peripheral blood, the simplicity of the OBP-401 method would be diminished by the introduction of antibody treatment. Therefore, we evaluated another approach to minimize the false positivity of WBCs. Seven anti-CD antibodies were employed to stain the species of WBCs that false-positively reacted with OBP-401. We revealed that the false-positively reacted WBCs were monocytes in the peripheral blood of both healthy subjects and cancer patients. Based on a size distribution analysis of the GFP-positive monocytes, the size criterion for CTCs using OBP-401 was defined to be a cellular diameter >8.4 μm. In total, 43% of 86 cancer patients examined in the present study were CTC-positive using this definition. CTCs were enumerated from peripheral blood samples collected from patients with each of the eight types of cancer; the detectability of CTCs for esophagus, pancreas and prostate cancers by the OBP-401 method was confirmed for the first time in the present study. However, no clear correlation between CTC positivity and the clinical characteristics of patients with any type of cancer was observed because of the small number of patients with each type of cancer. An additional clinical study will be conducted to confirm the clinical meaning of CTCs enumerated by OBP-401.

AB - We developed a detection method for circulating tumor cells (CTCs) using the telomerase-specific adenovirus OBP-401. This recombinant virus has a telomerase promoter at the 5'-end of the viral genome and GFP at the 3'-end. To date, CTC enumeration using OBP-401 has shown prognostic impact for gastric and small cell lung cancer patients. In the present study, peripheral blood samples from patients with eight types of cancer, including some cancers previously untested with OBP-401 (i.e., esophagus, pancreas, and prostate cancers) were subjected to this method in order to evaluate its versatility. It was recently discovered that some white blood cells (WBCs) false-positively react with OBP-401. Although anti-CD45 antibodies can absorb these adverse cells from peripheral blood, the simplicity of the OBP-401 method would be diminished by the introduction of antibody treatment. Therefore, we evaluated another approach to minimize the false positivity of WBCs. Seven anti-CD antibodies were employed to stain the species of WBCs that false-positively reacted with OBP-401. We revealed that the false-positively reacted WBCs were monocytes in the peripheral blood of both healthy subjects and cancer patients. Based on a size distribution analysis of the GFP-positive monocytes, the size criterion for CTCs using OBP-401 was defined to be a cellular diameter >8.4 μm. In total, 43% of 86 cancer patients examined in the present study were CTC-positive using this definition. CTCs were enumerated from peripheral blood samples collected from patients with each of the eight types of cancer; the detectability of CTCs for esophagus, pancreas and prostate cancers by the OBP-401 method was confirmed for the first time in the present study. However, no clear correlation between CTC positivity and the clinical characteristics of patients with any type of cancer was observed because of the small number of patients with each type of cancer. An additional clinical study will be conducted to confirm the clinical meaning of CTCs enumerated by OBP-401.

KW - Adenovirus

KW - Circulating tumor cells

KW - OBP-401

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=84907285388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907285388&partnerID=8YFLogxK

U2 - 10.3892/or.2014.3436

DO - 10.3892/or.2014.3436

M3 - Article

C2 - 25176113

AN - SCOPUS:84907285388

VL - 32

SP - 1772

EP - 1778

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -